Valuation ratios measure the quantity of an asset or flaw (e.g., earnings) associated with ownership of a specified claim (e.g., a share of ownership of the enterprise).
Paying user area
Try for free
Abbott Laboratories pages available for free this week:
- Income Statement
- Analysis of Profitability Ratios
- Analysis of Short-term (Operating) Activity Ratios
- Analysis of Reportable Segments
- Capital Asset Pricing Model (CAPM)
- Dividend Discount Model (DDM)
- Selected Financial Data since 2005
- Operating Profit Margin since 2005
- Return on Equity (ROE) since 2005
- Total Asset Turnover since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Abbott Laboratories for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Historical Valuation Ratios (Summary)
Based on: 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31).
The financial ratios exhibit notable trends over the periods analyzed, reflecting changing valuation and market perceptions of the company’s performance.
- Price to Earnings (P/E) Ratio
- The P/E ratio demonstrates a general downward trend from 36.79 in March 2021 to 15.48 by September 2025. Initial quarters show a steady decline with a slight rebound in the quarters ending December 2022 through December 2023. However, from December 2023 onward, there is a sharp decrease, indicating the market’s growing expectation of earnings improvement or a valuation reset. This decline suggests either faster earnings growth relative to price or a reduction in price expectations.
- Price to Operating Profit (P/OP) Ratio
- The P/OP ratio follows a similar pattern to the P/E ratio, declining from 31.39 in March 2021 to 28.05 in September 2025, though with greater volatility. It experiences declines through 2022, followed by a rebound in the 2023 periods, and then a significant increase in late 2024 before falling again in 2025. The increased volatility compared to the P/E ratio may indicate fluctuations in operating profit margins or transient market sentiment shifts impacting valuation multiples tied directly to operations.
- Price to Sales (P/S) Ratio
- The P/S ratio shows a decrease from 5.64 in early 2021 to a low near 3.85 in late 2022, followed by a recovery to above 5.5 in late 2024, and then a modest decline to 4.94 by September 2025. This pattern points to fluctuations in sales valuations, with a dip possibly linked to reduced revenue growth or sales concerns, followed by an increased valuation relative to sales in the 2024 periods, suggesting either sales improvement or stronger market confidence.
- Price to Book Value (P/BV) Ratio
- The P/BV ratio decreases steadily from 6.27 at the outset in 2021 to 4.25 by late 2025. While some quarters show minor rebounds, the overall trend is downward, indicating that the market price of the company’s equity is approaching closer to its book value over time. This may suggest reduced growth expectations or increased asset base valuation, with a consistent pattern of de-escalation in market premium over book value.
Overall, the data reveal a trend of declining valuation multiples across earnings, operating profit, sales, and book value metrics over the observed period. The declining P/E and P/BV ratios imply a market adjustment toward lower valuation premiums possibly driven by earnings growth rates outpacing price increases, or cautious investor sentiment. The volatility observed in P/OP and P/S ratios during mid-periods indicates episodic shifts in operational profitability and sales growth perceptions. These trends collectively suggest a period of transition in market expectations and underlying financial fundamentals.
Price to Earnings (P/E)
| Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | |||||||||||||||||||||||||
| Selected Financial Data (US$) | |||||||||||||||||||||||||
| Net earnings (in millions) | |||||||||||||||||||||||||
| Earnings per share (EPS)2 | |||||||||||||||||||||||||
| Share price1, 3 | |||||||||||||||||||||||||
| Valuation Ratio | |||||||||||||||||||||||||
| P/E ratio4 | |||||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||||
| P/E Ratio, Competitors5 | |||||||||||||||||||||||||
| Elevance Health Inc. | |||||||||||||||||||||||||
| Intuitive Surgical Inc. | |||||||||||||||||||||||||
| Medtronic PLC | |||||||||||||||||||||||||
| UnitedHealth Group Inc. | |||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31).
1 Data adjusted for splits and stock dividends.
2 Q3 2025 Calculation
EPS
= (Net earningsQ3 2025
+ Net earningsQ2 2025
+ Net earningsQ1 2025
+ Net earningsQ4 2024)
÷ No. shares of common stock outstanding
= ( + + + )
÷ =
3 Closing price as at the filing date of Abbott Laboratories Quarterly or Annual Report.
4 Q3 2025 Calculation
P/E ratio = Share price ÷ EPS
= ÷ =
5 Click competitor name to see calculations.
- Share Price Trend
- The share price exhibited moderate fluctuations over the observed periods. Initially, there was an upward movement from early 2021 to the third quarter of 2021, peaking around September 2021. This was followed by a decline toward the end of 2021 and through much of 2022, reaching a low point in the third quarter of 2023. Subsequently, the price showed recovery and growth, particularly notable in the last four quarters, culminating in a peak in December 2024, before a slight decline again by the third quarter of 2025.
- Earnings per Share (EPS) Movement
- EPS steadily increased from the beginning of 2021 through mid-2022, indicating a period of improving profitability. However, a downturn was observed through 2023, with consistent declines noted in EPS values. This was followed by a significant upward trend starting in late 2023, with EPS nearly doubling from early 2024 onwards, suggesting enhanced earning capacity in the final periods analyzed.
- Price-to-Earnings (P/E) Ratio Dynamics
- The P/E ratio demonstrated a declining trend from early 2021 until mid-2022, reflecting either a market revaluation or improved earnings growth relative to price. During late 2022 and early 2023, the ratio increased, coinciding with declining EPS and varied share price. From mid-2024 onward, the P/E ratio exhibited a sharp decrease, reaching notably low levels by late 2025 despite the strong EPS gains, indicating that the stock price did not increase proportionately with earnings growth during this later period.
- Summary Insights
- Overall, the data reflect an initial phase of growth for both share price and earnings, followed by a period of volatility and reduced profitability around 2023. A robust earnings recovery is evident starting from late 2023 through 2025. Despite this earnings improvement, the market valuation as indicated by the P/E ratio decreased significantly in the latter periods, which could suggest market skepticism, price adjustment lag, or changes in investor expectations relative to earnings performance.
Price to Operating Profit (P/OP)
| Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | |||||||||||||||||||||||||
| Selected Financial Data (US$) | |||||||||||||||||||||||||
| Operating earnings (in millions) | |||||||||||||||||||||||||
| Operating profit per share2 | |||||||||||||||||||||||||
| Share price1, 3 | |||||||||||||||||||||||||
| Valuation Ratio | |||||||||||||||||||||||||
| P/OP ratio4 | |||||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||||
| P/OP Ratio, Competitors5 | |||||||||||||||||||||||||
| Elevance Health Inc. | |||||||||||||||||||||||||
| Intuitive Surgical Inc. | |||||||||||||||||||||||||
| Medtronic PLC | |||||||||||||||||||||||||
| UnitedHealth Group Inc. | |||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31).
1 Data adjusted for splits and stock dividends.
2 Q3 2025 Calculation
Operating profit per share
= (Operating earningsQ3 2025
+ Operating earningsQ2 2025
+ Operating earningsQ1 2025
+ Operating earningsQ4 2024)
÷ No. shares of common stock outstanding
= ( + + + )
÷ =
3 Closing price as at the filing date of Abbott Laboratories Quarterly or Annual Report.
4 Q3 2025 Calculation
P/OP ratio = Share price ÷ Operating profit per share
= ÷ =
5 Click competitor name to see calculations.
The financial data reveals several notable trends in key performance indicators over the observed periods. The share price fluctuates considerably, showing an initial upward movement followed by a decline, and a rebound in later quarters. Operating profit per share demonstrates moderate volatility but maintains an overall increasing trend in the long term. The price-to-operating profit ratio (P/OP) presents variations that correspond inversely with changes in share price and operating profit per share, indicating market valuation shifts relative to earnings.
- Share Price Trends
- The share price starts at $118.51 and generally declines through the middle periods, reaching lows near $95.01. Thereafter, it experiences recovery phases, notably a sharp rise to $134.92 by December 2024, followed by a slight decline towards $124.43 in September 2025. This suggests market sentiment and external factors influencing price volatility, with significant recovery late in the period under review.
- Operating Profit Per Share Movements
- The operating profit per share increases from $3.78 in March 2021 to a peak near $5.83 in June 2022 before experiencing a downward correction to roughly $3.46 by September 2023. Thereafter, it resumes a gradual ascending trajectory, reaching $4.44 by September 2025. This pattern reflects underlying earnings strength that faced short term pressures but regained momentum subsequently.
- Price to Operating Profit Ratio (P/OP)
- The P/OP ratio starts high at 31.39, declines steadily to a low near 18.35 in September 2022, and then rises again sharply, peaking above 34 by December 2024 before tapering down slightly thereafter. These fluctuations indicate changing investor valuation multiples that may correspond to shifting expectations on growth prospects and risk perceptions relative to operating profitability.
- Interrelations and Insights
- An inverse relationship between the P/OP ratio and operating profit per share is observable during several intervals; when earnings per share increase, the ratio tends to decline, suggesting improving earnings relative to price, and vice versa. The late period share price recovery, despite moderate earnings increases, results in elevated P/OP ratios, signaling possibly increased market optimism or speculative valuation.
Price to Sales (P/S)
| Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | |||||||||||||||||||||||||
| Selected Financial Data (US$) | |||||||||||||||||||||||||
| Net sales (in millions) | |||||||||||||||||||||||||
| Sales per share2 | |||||||||||||||||||||||||
| Share price1, 3 | |||||||||||||||||||||||||
| Valuation Ratio | |||||||||||||||||||||||||
| P/S ratio4 | |||||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||||
| P/S Ratio, Competitors5 | |||||||||||||||||||||||||
| Elevance Health Inc. | |||||||||||||||||||||||||
| Intuitive Surgical Inc. | |||||||||||||||||||||||||
| Medtronic PLC | |||||||||||||||||||||||||
| UnitedHealth Group Inc. | |||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31).
1 Data adjusted for splits and stock dividends.
2 Q3 2025 Calculation
Sales per share
= (Net salesQ3 2025
+ Net salesQ2 2025
+ Net salesQ1 2025
+ Net salesQ4 2024)
÷ No. shares of common stock outstanding
= ( + + + )
÷ =
3 Closing price as at the filing date of Abbott Laboratories Quarterly or Annual Report.
4 Q3 2025 Calculation
P/S ratio = Share price ÷ Sales per share
= ÷ =
5 Click competitor name to see calculations.
The share price exhibits fluctuations over the analyzed periods, beginning at $118.51 and experiencing a general downward trend toward $99.31 by the third quarter of 2022. Following this low, there is a notable recovery and increase, culminating in a peak of $134.92 in the fourth quarter of 2024. Subsequent months show a slight decline but the price remains relatively strong, ending at $124.43 in the third quarter of 2025.
Sales per share demonstrate a comparatively steadier pattern, with a gradual upward movement overall. Starting from $21.01, sales per share increase consistently with minor variations, reaching $25.21 by the third quarter of 2025. This indicates a slow but steady growth in revenue generation per share over the timeframe considered.
The price-to-sales (P/S) ratio shows more volatility throughout the periods. Initially, the ratio decreases from 5.64 to a low of 3.85 by the third quarter of 2022, suggesting a decline in valuation multiples relative to sales. After this trough, the P/S ratio rebounds sharply, reaching 5.58 in the fourth quarter of 2024, reflecting increased market confidence or improved market valuation. Toward the latest periods, the ratio slightly decreases again but remains elevated compared to earlier lows.
Overall, the data reveals a cyclical pattern in market valuation metrics, with share price and P/S ratio falling to lows around mid-2022 before recovering strongly into 2024. Sales per share persist on a steady upward trend during the entire period, indicating positive underlying business performance. The divergence in the amplitude of movements between share price and sales suggests changing investor sentiment and market conditions influencing valuation multiples independently from sales growth trends.
- Share Price Trends
- Initial decline through mid-2022, strong recovery to late 2024 peak, slight decline thereafter.
- Sales Per Share Patterns
- Steady increase from $21.01 to $25.21 over the period, indicating growth in sales on per-share basis.
- P/S Ratio Behavior
- Decline to low in mid-2022 followed by sharp rebound, implying fluctuating investor valuation apart from sales growth.
- Implications
- Underlying business shows consistent sales growth, while market pricing exhibits volatility influenced by external factors affecting valuation multiples.
Price to Book Value (P/BV)
| Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | |||||||||||||||||||||||||
| Selected Financial Data (US$) | |||||||||||||||||||||||||
| Total Abbott shareholders’ investment (in millions) | |||||||||||||||||||||||||
| Book value per share (BVPS)2 | |||||||||||||||||||||||||
| Share price1, 3 | |||||||||||||||||||||||||
| Valuation Ratio | |||||||||||||||||||||||||
| P/BV ratio4 | |||||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||||
| P/BV Ratio, Competitors5 | |||||||||||||||||||||||||
| Elevance Health Inc. | |||||||||||||||||||||||||
| Intuitive Surgical Inc. | |||||||||||||||||||||||||
| Medtronic PLC | |||||||||||||||||||||||||
| UnitedHealth Group Inc. | |||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31).
1 Data adjusted for splits and stock dividends.
2 Q3 2025 Calculation
BVPS = Total Abbott shareholders’ investment ÷ No. shares of common stock outstanding
= ÷ =
3 Closing price as at the filing date of Abbott Laboratories Quarterly or Annual Report.
4 Q3 2025 Calculation
P/BV ratio = Share price ÷ BVPS
= ÷ =
5 Click competitor name to see calculations.
- Share Price Trend
- The share price exhibited moderate fluctuations over the period analyzed. Initially, it rose from $118.51 to a peak of $128.70 in September 2021, followed by a general decline reaching a low of $95.01 in September 2023. After this low point, the share price recovered significantly, achieving a high of $134.92 by December 2024 before slightly tapering off to $124.43 in September 2025. The trend indicates a period of volatility with a mid-term decline, followed by a robust rebound towards the latter part of the timeline.
- Book Value Per Share (BVPS) Trend
- The book value per share demonstrated a steady and consistent upward trajectory throughout the entire timespan. Starting at $18.89 in March 2021, it increased gradually each quarter, reaching $29.30 by September 2025. This increase reflects an overall strengthening of the company's net asset value per share, suggesting improvements in equity capital or retained earnings accumulation over the period.
- Price to Book Value Ratio (P/BV) Analysis
- The price-to-book value ratio showed a general downward trend from 6.27 at the start of the period to 4.25 in September 2025. This decline indicates that the market price grew at a slower pace compared to book value, or that market valuation became more conservative relative to the company's net assets. Notably, the P/BV ratio reached a local minimum around September 2023 coinciding with the lowest share price point and subsequently experienced some fluctuations but remained on a decreasing trend toward the end.
- Overall Interpretation
- The company's net book value has steadily increased, reflecting growing shareholder equity. Meanwhile, share price movements were more volatile, experiencing both notable declines and recoveries. The falling price-to-book ratio suggests that the market valuation adjusted to a lower premium relative to book value, potentially reflecting changes in market sentiment or risk assessments. The recent recovery in share price coupled with continued growth in book value per share points to improved investor confidence towards the latter quarters.